Back to top
more

Amphastar Pharmaceuticals (AMPH)

(Delayed Data from NSDQ)

$21.21 USD

21.21
440,154

+0.26 (1.24%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $21.21 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Falling Earnings Estimates Signal Weakness Ahead for Amphastar (AMPH)

by Zacks Equity Research

Amphastar (AMPH) has witnessed a significant price decline in the past four weeks, and has seen negative earnings estimate revisions for the current quarter and year.

    Zacks Equity Research

    New Strong Sell Stocks for May 15th

    by Zacks Equity Research

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

      Zacks Equity Research

      Mallinckrodt PLC (MNK) Jumps: Stock Rises 15.3%

      by Zacks Equity Research

      Mallinckrodt PLC (MNK) shares rose more than 15% in the last trading session, amid huge volumes.

        Zacks Equity Research

        Key Factors to Influence Penumbra's (PEN) Earnings in Q4

        by Zacks Equity Research

        Penumbra (PEN) expects to gain from solid performance by neuro and peripheral vascular arms in Q4. Strong growth across all geographies is likely to drive the top line.

          Zacks Equity Research

          What's in Store for Veeva Systems (VEEV) in Q4 Earnings?

          by Zacks Equity Research

          Consistent focus on Subscription Services is likely to drive Veeva Systems (VEEV) in Q4.

            Zacks Equity Research

            Is a Beat in Store for Inogen (INGN) This Earnings Season?

            by Zacks Equity Research

            Strong product portfolio and a unique direct-to-consumer business model are expected to drive Inogen (INGN) in Q4.

              Zacks Equity Research

              Can PBM Unit Drive Express Scripts' (ESRX) Earnings in Q4?

              by Zacks Equity Research

              Express Scripts (ESRX) expects Q4 results to show earnings growth on strength in PBM segment.

                Zacks Equity Research

                Abiomed's Extended FDA Nod for Impella Boosts Women Health

                by Zacks Equity Research

                Abiomed (ABMD) boosts cardiomyopathy treatment with the extended FDA nod for Impella. This parallelly bolsters women's cardiac treatment.

                  Zacks Equity Research

                  CVS Health (CVS) Plans to Boost Hourly Minimum Wage Rate

                  by Zacks Equity Research

                  CVS Health (CVS) raises minimum wage level on benefits earned from tax savings. The company plans to put the remaining savings back into the business.

                    Zacks Equity Research

                    5 Reasons to Invest in PerkinElmer (PKI) Stock Right Now

                    by Zacks Equity Research

                    PerkinElmer (PKI) rides on synergies from the acquisition of EUROIMMUN and broadened product base.

                      Zacks Equity Research

                      Will Global Industrial Unit Aid Ecolab (ECL) in Q4 Earnings?

                      by Zacks Equity Research

                      Ecolab's (ECL) strong segmental sales and acquisition-driven strategies are likely to drive fourth-quarter results.

                        Zacks Equity Research

                        Henry Schein (HSIC) Q4 Earnings to Show Growth in All Lines?

                        by Zacks Equity Research

                        Henry Schein (HSIC) likely to gain on strength across all business segments in Q4.

                          Zacks Equity Research

                          AmerisourceBergen (ABC) Gains on World Courier Unit Strength

                          by Zacks Equity Research

                          AmerisourceBergen's (ABC) World Courier business gets GDP designation.

                            Zacks Equity Research

                            Can Pharmacy Services Drive CVS Health's (CVS) Q4 Earnings?

                            by Zacks Equity Research

                            CVS Health's (CVS) Q4 earnings are expected to gain from strength in the Pharmacy Services segment.

                              Zacks Equity Research

                              What's in Store for Cardinal Health (CAH) in Q2 Earnings?

                              by Zacks Equity Research

                              Pricing pressure in generics portfolio is likely to mar Cardinal Health's (CAH) top line in Q2.

                                Zacks Equity Research

                                Can Molecular Diagnostics Arm Up Hologic (HOLX) Q1 Earnings?

                                by Zacks Equity Research

                                Molecular Diagnostics unit's stellar performance in the first quarter of 2018 is likely to drive Hologic (HOLX) in Q1.

                                  Zacks Equity Research

                                  Will Higher System Sales Drive Cerner's (CERN) Q4 Earnings?

                                  by Zacks Equity Research

                                  Cerner (CERN) expects solid Q4 revenues on a surge in bookings. Stiff competition remains a concern.

                                    Zacks Equity Research

                                    Amphastar (AMPH) in Focus: Stock Moves 9.7% Higher

                                    by Zacks Equity Research

                                    Amphastar Pharmaceuticals (AMPH) was a big mover last session, as the company saw its shares rise almost 10% on the day.

                                      Arpita Dutt headshot

                                      Pharma Stock Roundup: Cempra Plunges to 52-Week Low, Shire Drug Label Expanded

                                      by Arpita Dutt

                                      Key highlights this week include complete response letters from the FDA for a couple of companies with Cempra (CEMP) plunging to a 52-week low.

                                        Zacks Equity Research

                                        Amphastar Stock Down on CRL for Asthma Drug in the U.S.

                                        by Zacks Equity Research

                                        Amphastar Pharmaceuticals, Inc. (AMPH) announced that its subsidiary, Armstrong Pharmaceuticals, Inc., has received a Complete Response Letter (CRL) from the FDA for Primatene Mist (epinephrine inhalation aerosol).